Appraisal 230

NICE Single Technology Appraisal Guidance No 230

Bivalirudin for the treatment of ST-segment-elevation myocardial infarction

This NICE guidance was published on27th July 2011. The web reference for the appraisal and other related documents is: www.nice.org.uk/TA230

NHSScotland should note that:

1. Recommendations of NICE Single Technology Appraisals (STAs) have no status in NHSScotland.

2. NHS boards should adhere to the Scottish Medicines Consortium (SMC) advice.

SMC published a Statement of Advice (638/10) on this medication for this indication in September 2010. This stated that:

Bivalirudin (Angiox)is accepted for use within NHS Scotland as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Bivalirudin should be administered with aspirin and clopidogrel. Its use is restricted topatients who would have been considered for treatment with heparin in combination with a glycoprotein IIb/IIIa inhibitor. It should not be used as an alternative to heparin alone.

Access the advice of SMC

3. There is no material difference between the recommendations of the NICE STA and SMC.

If you need further assistance, please contact Eleanor Brownlee in the first instance (tel 0141 225 6873 or email eleanor.brownlee@nhs.net).

Published Date: 27 July 2011

Evidence

Reviewed for Scotland

This advice has been reviewed under our procedure for processing NICE appraisals to ensure it is relevant for the Scottish healthcare landscape.

Read our process for reviewing NICE guidance